hydroxyurea has been researched along with Disease Models, Animal in 101 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-Lipoxygenase inhibitor zileuton has been demonstrated to attenuate ischemic brain damage in rats of permanent focal cerebral ischemia in previous work." | 7.76 | Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats. ( Chen, CM; Jin, CD; Shi, SS; Tu, XK; Wang, CH; Wen, S; Yang, WZ; Yang, YK; Zhang, YL, 2010) |
| "Combination therapy blocking both PAF and histamine markedly reduces the severity of peanut-induced anaphylaxis, and thus it may be a potential life-saving therapeutic approach in peanut and, likely, other food-induced anaphylaxis." | 7.75 | Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. ( Arias, K; Baig, M; Chu, D; Colangelo, M; Coyle, A; Goncharova, S; Jordana, M; Vadas, P; Walker, T; Waserman, S, 2009) |
| " Here, we investigate the effects of treatment with 5-LOX inhibitor zileuton in rats and targeted disruption of the 5-LOX gene in mice (5-LOX(-/-)) on multiple organ injury/dysfunction caused by severe endotoxemia." | 7.72 | Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. ( Collin, M; Collino, M; Cuzzocrea, S; Di Paola, R; Hadley, J; Patel, NS; Rossi, A; Sautebin, L; Thiemermann, C, 2004) |
| " A selective and potent 5-LO inhibitor, zileuton (N-1(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea, A-64077) was evaluated in models of airway anaphylaxis, where leukotrienes are a major component." | 7.69 | The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. ( Bell, RL; Brooks, DW; Carter, GW; Malo, PE; Shaughnessy, TK; Summers, JB, 1994) |
| "Recent studies demonstrated beneficial effects of zileuton, a 5-lipoxygenase (5LO) inhibitor, on some brain diseases in animal models, but the role of zileuton in the depression remains unknown." | 3.88 | Antidepressant-like effect of zileuton is accompanied by hippocampal neuroinflammation reduction and CREB/BDNF upregulation in lipopolysaccharide-challenged mice. ( Du, YF; Hong, H; Hu, M; Li, DD; Long, Y; Reed, MN; Suppiramaniam, V; Tang, SS; Xie, H, 2018) |
| "To determine 5-lipoxygenase (5-LOX) expression and the effect of zileuton, a selective 5-LOX inhibitor,on hippocampal neuron injury induced by global cerebral ischemia in rats." | 3.79 | [Expression of 5-lipoxygenase in hippocampal CA1 neuronal damage following global cerebral ischemia in rats]. ( Chen, W; Han, H; Li, C; Wei, E; Zhang, L; Zhang, X; Zhao, J, 2013) |
| "F10 mouse melanoma cells were partially synchronized with hydroxyurea, thymidine, or by mitotic shake-off." | 3.76 | The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. ( Annels, NE; Harrington, KJ; Heinemann, L; Melcher, A; Pandha, HS; Prestwich, R; Simpson, GR; Vile, R, 2010) |
| "5-Lipoxygenase inhibitor zileuton has been demonstrated to attenuate ischemic brain damage in rats of permanent focal cerebral ischemia in previous work." | 3.76 | Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats. ( Chen, CM; Jin, CD; Shi, SS; Tu, XK; Wang, CH; Wen, S; Yang, WZ; Yang, YK; Zhang, YL, 2010) |
| "Combination therapy blocking both PAF and histamine markedly reduces the severity of peanut-induced anaphylaxis, and thus it may be a potential life-saving therapeutic approach in peanut and, likely, other food-induced anaphylaxis." | 3.75 | Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. ( Arias, K; Baig, M; Chu, D; Colangelo, M; Coyle, A; Goncharova, S; Jordana, M; Vadas, P; Walker, T; Waserman, S, 2009) |
| "Two experiments were conducted to determine: 1) whether the adult male transgenic sickle cell mouse (Tg58 x Tg98; TSCM), exhibits the patterns of reproductive endpoints (hypogonadism) characteristic of men with sickle cell disease (SCD) and 2) whether hydroxyurea (HU) exacerbates this condition." | 3.75 | Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints. ( Aguinaga, MP; Archibong, AE; Bourne, P; Brooks, CM; Bruce, D; Hills, ER; Jones, KM; Niaz, MS; Rice, VM; Roberson, SI, 2009) |
| "Exposure to hydroxyurea caused a dose-dependent increase in fetal deaths that was not affected by hSOD1 expression; hydroxyurea decreased fetal weights in litters from wild-type but not hemizygous dams." | 3.75 | The impact of human superoxide dismutase 1 expression in a mouse model on the embryotoxicity of hydroxyurea. ( Hales, BF; Larouche, G, 2009) |
| "Capsaicin cough-reflex sensitivity and the number of BAL neutrophils were increased 6 hours after stimulus application, decreasing to control levels by 24 hours." | 3.74 | Effect of pressure stress applied to the airway on cough-reflex sensitivity in Guinea pigs. ( Fujimura, M; Hara, J; Kasahara, K; Kita, T; Myou, S; Ohkura, N; Oribe, Y; Ueda, A; Yasui, M, 2008) |
| " Treatment of the mice with zileuton or montelukast reduced the spinal cord inflammation and tissue injury, neutrophil infiltration, TNF-alpha, COX-2 and pERK1/2 expression, PGE(2) and LTB(4) production, and apoptosis." | 3.74 | Effects of zileuton and montelukast in mouse experimental spinal cord injury. ( Bramanti, P; Caminiti, R; Cuzzocrea, S; Di Paola, R; Genovese, T; Mazzon, E; Muià, C; Rossi, A; Sautebin, L, 2008) |
| " Here, we investigate the effects of treatment with 5-LOX inhibitor zileuton in rats and targeted disruption of the 5-LOX gene in mice (5-LOX(-/-)) on multiple organ injury/dysfunction caused by severe endotoxemia." | 3.72 | Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. ( Collin, M; Collino, M; Cuzzocrea, S; Di Paola, R; Hadley, J; Patel, NS; Rossi, A; Sautebin, L; Thiemermann, C, 2004) |
| " A selective and potent 5-LO inhibitor, zileuton (N-1(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea, A-64077) was evaluated in models of airway anaphylaxis, where leukotrienes are a major component." | 3.69 | The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. ( Bell, RL; Brooks, DW; Carter, GW; Malo, PE; Shaughnessy, TK; Summers, JB, 1994) |
| " It has been found that maternal administration of hydroxyurea, mitomycin C, or 5-fluorouracil on day 9 of pregnancy, that is, when the fetal neural tube is in the final stages of closure, leads to a significant reduction in the proportion of NTD (to 15 to 20%) in the offspring, while total litter size is unaffected." | 3.66 | The cause of neural tube defects: some experiments and a hypothesis. ( Seller, MJ, 1983) |
| " Accordingly, we conclude that clinical trials in SCD designed to increase the bioavailability of NO or association studies in which SCD clinical manifestations are related to plasma hemoglobin via its surrogates should be viewed with caution." | 2.46 | Pulmonary hypertension and nitric oxide depletion in sickle cell disease. ( Bunn, HF; Dover, GJ; Hebbel, RP; Nathan, DG; Platt, OS; Rosse, WF; Ware, RE, 2010) |
| "Idiopathic myelofibrosis is the least common and carries the worst prognosis of the chronic myeloproliferative disorders." | 2.40 | Pathogenesis and management of idiopathic myelofibrosis. ( Reilly, JT, 1998) |
| " Because SCD is associated with reduced nitric oxide (NO) bioavailability, we hypothesized that hydroxyurea treatment would improve NO bioavailability in the humanized sickle cell mouse." | 1.62 | Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice. ( Dunaway, LS; Kasztan, M; Molina, PA; Pollock, DM; Pollock, JS; Sedaka, R; Taylor, CM, 2021) |
| " However, this study found that the poor potency and oral bioavailability of compound 1 limits the development of this inducer for clinical use." | 1.62 | Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease. ( Chen, CT; Chou, YC; Hsieh, MY; Hsu, T; James Shen, CK; Jiaang, WT; Kung, FC; Lai, ZS; Lin, CH; Lu, CT; Yeh, TK, 2021) |
| "Zileuton is an FDA-approved drug for treating asthma and an ALOX5 inhibitor." | 1.62 | Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models. ( Li, L; Wang, S; Xiao, Y; Xu, Z, 2021) |
| "Zileuton and LY294002 were used to inhibit expression of 5-LOX and Akt, respectively." | 1.62 | 5-Lipoxygenase inhibition reduces inflammation and neuronal apoptosis via AKT signaling after subarachnoid hemorrhage in rats. ( Chen, H; Deng, Y; Guo, Z; He, Z; Liang, Y; Liu, L; Sun, X; Zhang, P; Zhang, Z, 2021) |
| " Conversely, DO mice lacking adverse liver pathology following zileuton exposure experienced decreased hepatic concentrations of resistin and increased concentrations of insulin and leptin, providing potential clues into mechanisms of toxicity resistance." | 1.56 | Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice. ( Bell, N; Gatti, DM; Harrill, AH; James, LP; Larson, GJ; Lyn-Cook, LE; Mattes, WB; Mayeux, PR; You, D, 2020) |
| "The complex pathophysiology of sickle cell anemia (SCA) involves intravascular hemolytic processes and recurrent vaso-occlusion, driven by chronic vascular inflammation, which result in the disease's severe clinical complications, including recurrent painful vaso-occlusive episodes." | 1.56 | Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies. ( Almeida, CB; Brito, PL; Brockschnieder, D; Chweih, H; Conran, N; Costa, FF; Ferreira, WA; Franco-Penteado, CF; Frenette, PS; Garcia, F; Gotardo, EMF; Lanaro, C; Leonardo, FC; Miguel, LI; Saad, STO; Sandner, P; Stasch, JP; Torres, L, 2020) |
| "Nimbolide is known to be an antioxidant found in neem plant." | 1.48 | Protective role of nimbolide against chemotherapeutic drug hydroxyurea induced genetic and oxidative damage in an animal model. ( Ahmad, MF; Ansari, MO; Jameel, S; Parveen, N; Shadab, GGHA; Siddique, HR; Wani, AL, 2018) |
| "In cultured ovarian cancer cells, 5-LOX metabolites were increased under hypoxic conditons." | 1.42 | Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. ( Fan, B; Gao, W; Li, B; Li, M; Liu, H; Qu, X; Shao, Q; Wang, Q; Wen, Z; Xie, Q; Yang, Y; Yu, J; Zhao, F, 2015) |
| "Hemolysis and consequent release of cell-free hemoglobin (CFHb) impair vascular nitric oxide (NO) bioavailability and cause oxidative and inflammatory processes." | 1.42 | Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. ( Almeida, CB; Conran, N; Costa, FF; Costa, FT; Covas, DT; Leonardo, FC; Souza, LE; Werneck, CC, 2015) |
| "5-Lipoxygenase (5LO) is upregulated in Alzheimer's disease (AD) and in vivo modulates the amyloidotic phenotype of amyloid precursor protein transgenic mice." | 1.40 | Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. ( Chu, J; Giannopoulos, PF; Joshi, YB; Kirby, LG; Li, JG; Praticò, D; Sperow, M, 2014) |
| "Hydroxyurea treatment decreased neutrophil extravasation into the infected lung coincident with significantly reduced levels of E-selectin in serum and on pulmonary epithelia." | 1.38 | Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. ( Gao, G; Howard, T; Hu, Y; Johnson, M; Lebensburger, JD; Persons, DA; Pestina, TI; Rosch, JW; Tuomanen, EI; Ware, RE; Zakharenko, SS, 2012) |
| "Pomalidomide is a potent structural analog of thalidomide and member of a new class of immunomodulatory drugs." | 1.37 | Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. ( Corral, LG; Kutlar, A; Kutlar, F; Meiler, SE; Moutouh-de Parseval, LA; Swerdlow, PS; Wade, M; Xue, Y; Yerigenahally, SD, 2011) |
| "Hydroxyurea has proven clinical efficacy in patients with sickle cell disease." | 1.36 | Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. ( Boyd, KL; Lebensburger, JD; Persons, DA; Pestina, TI; Ware, RE, 2010) |
| "Inflammation was produced by adding carrageenan into a newly formed air pouch and prostaglandins produced." | 1.35 | A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. ( Anderson, GD; Dufield, DR; Hardy, MM; Masferrer, JL; Pufahl, RA; Zweifel, BS, 2008) |
| "Skin cancer is the most common cancer, and often occurs in the head and neck region." | 1.35 | Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. ( Fegn, L; Wang, Z, 2009) |
| " Hydroxyurea completely eliminated Leishmania parasites when it was used at a dosage of 10 or 100 microg/ml." | 1.35 | Activity of hydroxyurea against Leishmania mexicana. ( Galindo-Sevilla, N; Mancilla-Ramirez, J; Martinez-Rojano, H; Quiñonez-Diaz, L, 2008) |
| " Both S-29606 and S-30621 were dosed via nose-only inhalation 5 days a week, for 16 weeks, whereas Zileuton was administered orally." | 1.34 | Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation. ( Angersbach, BS; Karlage, K; Kuehl, PJ; Merrill, BA; Myrdal, PB; Wightman, PD, 2007) |
| " In this study, the novel RR inhibitors didox (DX; 3,4-dihydroxybenzohydroxamic acid), and trimidox (TX; 3,4,5-trihydroxybenzamidoxime) were evaluated along with HU for anti-retroviral efficacy in LPBM5-induced retro-viral disease (MAIDS) both as monotherapeutic regimens and in combination with the guanine containing NRTI abacavir (ABC)." | 1.32 | In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease. ( Duvall, W; Elford, HL; Gallicchio, VS; Hagan, E; Inayat, MS; Mayhew, CN; Sumpter, LR; Yost, EE, 2004) |
| " 70C and 360C were dosed to female Wistar rats at 100 mg/kg po daily for 7 days." | 1.30 | Structure-activity relationship for two lipoxygenase inhibitors and their potential for inducing nephrotic syndrome. ( Evans, GO; Goodwin, DA; Hawksworth, GM; Hodgson, ST; Morley, TJ; Read, NG, 1997) |
| " Therefore, in this study, we determined if multiple dosing with zileuton, which theoretically could improve tissue levels, would provide protection against the antigen-induced EAR as well as the LAR." | 1.30 | The effects of multiple dosing with zileuton on antigen-induced responses in sheep. ( Abraham, WM; Allegra, L; Scuri, M, 1998) |
| "BW B70C treatment did not improve the long-term viability of transplanted kidneys: 2/6 rabbits showed no symptoms of renal failure after 3 weeks." | 1.29 | Inhibition of leukotriene B4 synthesis does not prevent development of acute renal failure following storage and transplantation. ( Fuller, BJ; Green, CJ; Lane, NJ; Manek, S; Thorniley, MS, 1994) |
| "Paul, Director of the Office of AIDS Research (OAR) at the U." | 1.29 | Basic science and clinical trials: interview with William Paul, director of the Office of AIDS Research. Interview by John S James. ( Paul, W, 1995) |
| "Zileuton was approximately 40 times less potent." | 1.28 | Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. ( Crawley, GC; Foster, SJ; McMillan, RM; Spruce, KE; Walker, ER, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (7.92) | 18.7374 |
| 1990's | 14 (13.86) | 18.2507 |
| 2000's | 23 (22.77) | 29.6817 |
| 2010's | 44 (43.56) | 24.3611 |
| 2020's | 12 (11.88) | 2.80 |
| Authors | Studies |
|---|---|
| Martinez-Rojano, H | 1 |
| Mancilla-Ramirez, J | 1 |
| Quiñonez-Diaz, L | 1 |
| Galindo-Sevilla, N | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Lai, ZS | 1 |
| Yeh, TK | 1 |
| Chou, YC | 1 |
| Hsu, T | 1 |
| Lu, CT | 1 |
| Kung, FC | 1 |
| Hsieh, MY | 1 |
| Lin, CH | 1 |
| Chen, CT | 1 |
| James Shen, CK | 1 |
| Jiaang, WT | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Li, L | 1 |
| Xiao, Y | 2 |
| Xu, Z | 1 |
| Wang, S | 3 |
| Brito, PL | 2 |
| Dos Santos, AF | 2 |
| Chweih, H | 2 |
| Favero, ME | 1 |
| Gotardo, EMF | 2 |
| Silva, JAF | 1 |
| Leonardo, FC | 4 |
| Franco-Penteado, CF | 4 |
| de Oliveira, MG | 1 |
| Ferreira, WA | 2 |
| Zaidan, BC | 1 |
| Billis, A | 1 |
| Baldanzi, G | 1 |
| Mashima, DA | 1 |
| Antunes, E | 1 |
| Saad, STO | 2 |
| Costa, FF | 6 |
| Conran, N | 5 |
| Li, S | 2 |
| Kong, J | 1 |
| Yu, L | 1 |
| Liu, Q | 1 |
| Lee, JJ | 1 |
| Chang-Chien, GP | 1 |
| Lin, S | 1 |
| Hsiao, YT | 1 |
| Ke, MC | 1 |
| Chen, A | 1 |
| Lin, TK | 1 |
| Wu, QQ | 1 |
| Deng, W | 1 |
| Chen, JJ | 1 |
| Liu, C | 1 |
| Wang, J | 1 |
| Guo, Y | 1 |
| Duan, M | 1 |
| Cai, Z | 1 |
| Xie, S | 1 |
| Yuan, Y | 1 |
| Tang, Q | 1 |
| You, D | 1 |
| Lyn-Cook, LE | 1 |
| Gatti, DM | 1 |
| Bell, N | 1 |
| Mayeux, PR | 1 |
| James, LP | 1 |
| Mattes, WB | 1 |
| Larson, GJ | 1 |
| Harrill, AH | 1 |
| Santos Neto, ATD | 1 |
| Silva, IS | 1 |
| Ivo, ML | 1 |
| Rodrigues, CT | 1 |
| Parisotto, EB | 1 |
| Ramalho, RT | 1 |
| Monteiro, GM | 1 |
| Lanaro, C | 3 |
| Almeida, CB | 4 |
| Torres, L | 1 |
| Miguel, LI | 1 |
| Garcia, F | 1 |
| Frenette, PS | 2 |
| Brockschnieder, D | 1 |
| Stasch, JP | 1 |
| Sandner, P | 1 |
| Pardanani, A | 1 |
| Taylor, CM | 1 |
| Kasztan, M | 2 |
| Sedaka, R | 1 |
| Molina, PA | 1 |
| Dunaway, LS | 1 |
| Pollock, JS | 2 |
| Pollock, DM | 2 |
| Liu, L | 1 |
| Zhang, P | 1 |
| Zhang, Z | 1 |
| Liang, Y | 1 |
| Chen, H | 1 |
| He, Z | 1 |
| Sun, X | 1 |
| Guo, Z | 2 |
| Deng, Y | 1 |
| Curto-Garcia, N | 1 |
| Harrison, CN | 1 |
| Silva, FH | 1 |
| Fertrin, KY | 1 |
| Dos Santos, JL | 1 |
| Wade, M | 2 |
| Yerigenahally, S | 1 |
| de Melo, TR | 1 |
| Chin, CM | 1 |
| Kutlar, A | 2 |
| Meiler, SE | 2 |
| Li, DD | 1 |
| Xie, H | 1 |
| Du, YF | 1 |
| Long, Y | 1 |
| Reed, MN | 1 |
| Hu, M | 1 |
| Suppiramaniam, V | 1 |
| Hong, H | 1 |
| Tang, SS | 1 |
| Giannopoulos, PF | 3 |
| Chiu, J | 1 |
| Praticò, D | 3 |
| Ahmad, MF | 1 |
| Ansari, MO | 1 |
| Jameel, S | 1 |
| Wani, AL | 1 |
| Parveen, N | 1 |
| Siddique, HR | 1 |
| Shadab, GGHA | 1 |
| Kundu, MC | 1 |
| Gore, LR | 1 |
| Maguire, S | 1 |
| Gilmartin, AG | 1 |
| Taylor, C | 1 |
| Tao, B | 1 |
| Guy, A | 1 |
| Gourdou-Latyszenok, V | 1 |
| Le Lay, N | 1 |
| Peghaire, C | 1 |
| Kilani, B | 1 |
| Dias, JV | 1 |
| Duplaa, C | 1 |
| Renault, MA | 1 |
| Denis, C | 1 |
| Villeval, JL | 1 |
| Boulaftali, Y | 1 |
| Jandrot-Perrus, M | 1 |
| Couffinhal, T | 1 |
| James, C | 1 |
| Islam, W | 1 |
| Fang, J | 1 |
| Imamura, T | 1 |
| Etrych, T | 1 |
| Subr, V | 1 |
| Ulbrich, K | 1 |
| Maeda, H | 1 |
| Sasaki, F | 1 |
| Koga, T | 1 |
| Ohba, M | 1 |
| Saeki, K | 1 |
| Okuno, T | 1 |
| Ishikawa, K | 1 |
| Nakama, T | 1 |
| Nakao, S | 1 |
| Yoshida, S | 1 |
| Ishibashi, T | 1 |
| Ahmadieh, H | 1 |
| Kanavi, MR | 1 |
| Hafezi-Moghadam, A | 1 |
| Penninger, JM | 1 |
| Sonoda, KH | 1 |
| Yokomizo, T | 1 |
| Brose, RD | 1 |
| Lehrmann, E | 1 |
| Zhang, Y | 1 |
| Reeves, RH | 1 |
| Smith, KD | 1 |
| Mattson, MP | 1 |
| Piccin, A | 1 |
| Murphy, C | 1 |
| Eakins, E | 1 |
| Rondinelli, MB | 1 |
| Daves, M | 1 |
| Vecchiato, C | 1 |
| Wolf, D | 1 |
| Mc Mahon, C | 1 |
| Smith, OP | 1 |
| Park, F | 1 |
| Soni, H | 1 |
| Pressly, JD | 1 |
| Adebiyi, A | 1 |
| Chu, J | 2 |
| Joshi, YB | 1 |
| Sperow, M | 2 |
| Li, JG | 2 |
| Kirby, LG | 2 |
| Chen, W | 1 |
| Li, C | 1 |
| Zhao, J | 1 |
| Zhang, X | 1 |
| Han, H | 1 |
| Wei, E | 1 |
| Zhang, L | 1 |
| Solomon, LA | 1 |
| Russell, BA | 1 |
| Watson, LA | 1 |
| Beier, F | 1 |
| Bérubé, NG | 1 |
| Singh, P | 1 |
| Liew, WK | 1 |
| Darras, BT | 1 |
| Wen, Z | 1 |
| Liu, H | 1 |
| Li, M | 1 |
| Li, B | 1 |
| Gao, W | 1 |
| Shao, Q | 1 |
| Fan, B | 1 |
| Zhao, F | 1 |
| Wang, Q | 1 |
| Xie, Q | 1 |
| Yang, Y | 1 |
| Yu, J | 1 |
| Qu, X | 1 |
| Brugnerotto, AF | 1 |
| Roversi, FM | 1 |
| Pallis, FR | 1 |
| Albuquerque, DM | 1 |
| Rzodkiewicz, P | 1 |
| Gasinska, E | 1 |
| Maslinski, S | 1 |
| Bujalska-Zadrozny, M | 1 |
| Gounaris, E | 1 |
| Heiferman, MJ | 1 |
| Heiferman, JR | 1 |
| Shrivastav, M | 1 |
| Vitello, D | 1 |
| Blatner, NR | 1 |
| Knab, LM | 1 |
| Phillips, JD | 1 |
| Cheon, EC | 1 |
| Grippo, PJ | 1 |
| Khazaie, K | 1 |
| Munshi, HG | 1 |
| Bentrem, DJ | 1 |
| Yu, WH | 1 |
| Abood, M | 1 |
| Rivers, A | 1 |
| Vaitkus, K | 1 |
| Ruiz, MA | 1 |
| Ibanez, V | 1 |
| Jagadeeswaran, R | 1 |
| Kouznetsova, T | 1 |
| DeSimone, J | 2 |
| Lavelle, D | 1 |
| Souza, LE | 1 |
| Costa, FT | 1 |
| Werneck, CC | 1 |
| Covas, DT | 1 |
| Silva, BC | 1 |
| de Miranda, AS | 1 |
| Rodrigues, FG | 1 |
| Silveira, AL | 1 |
| Resende, GH | 1 |
| Moraes, MF | 1 |
| de Oliveira, AC | 1 |
| Parreiras, PM | 1 |
| Barcelos, Lda S | 1 |
| Teixeira, MM | 1 |
| Machado, FS | 1 |
| Teixeira, AL | 1 |
| Rachid, MA | 1 |
| Eiymo Mwa Mpollo, MS | 1 |
| Brandt, EB | 1 |
| Shanmukhappa, SK | 1 |
| Arumugam, PI | 1 |
| Tiwari, S | 1 |
| Loberg, A | 1 |
| Pillis, D | 1 |
| Rizvi, T | 1 |
| Lindsey, M | 1 |
| Jonck, B | 1 |
| Carmeliet, P | 1 |
| Kalra, VK | 1 |
| Le Cras, TD | 1 |
| Ratner, N | 1 |
| Wills-Karp, M | 1 |
| Hershey, GK | 1 |
| Malik, P | 1 |
| Martí, J | 1 |
| Santa-Cruz, MC | 1 |
| Serra, R | 1 |
| Hervás, JP | 1 |
| Kim, K | 1 |
| Li, J | 1 |
| Barazia, A | 1 |
| Tseng, A | 1 |
| Youn, SW | 1 |
| Abbadessa, G | 1 |
| Yu, Y | 1 |
| Schwartz, B | 1 |
| Andrews, RK | 1 |
| Gordeuk, VR | 1 |
| Cho, J | 1 |
| Chen, Y | 1 |
| Shan, Y | 1 |
| Lu, M | 1 |
| DeSouza, N | 1 |
| Hoffman, R | 1 |
| Liang, A | 1 |
| Abueid, L | 1 |
| Uslu, Ü | 1 |
| Cumbul, A | 1 |
| Velioğlu Öğünç, A | 1 |
| Ercan, F | 1 |
| Alican, İ | 1 |
| Svouraki, A | 1 |
| Garscha, U | 1 |
| Kouloura, E | 1 |
| Pace, S | 1 |
| Pergola, C | 2 |
| Krauth, V | 1 |
| Rossi, A | 4 |
| Sautebin, L | 5 |
| Halabalaki, M | 1 |
| Werz, O | 2 |
| Gaboriaud-Kolar, N | 1 |
| Skaltsounis, AL | 1 |
| Mattis, VB | 1 |
| Butchbach, ME | 1 |
| Lorson, CL | 1 |
| Marusic, S | 1 |
| Thakker, P | 1 |
| Pelker, JW | 1 |
| Stedman, NL | 1 |
| Lee, KL | 1 |
| McKew, JC | 1 |
| Han, L | 1 |
| Xu, X | 1 |
| Wolf, SF | 1 |
| Borey, AJ | 1 |
| Cui, J | 1 |
| Shen, MW | 1 |
| Donahue, F | 1 |
| Hassan-Zahraee, M | 1 |
| Leach, MW | 1 |
| Shimizu, T | 1 |
| Clark, JD | 1 |
| Fegn, L | 1 |
| Wang, Z | 1 |
| Arias, K | 1 |
| Baig, M | 1 |
| Colangelo, M | 1 |
| Chu, D | 1 |
| Walker, T | 1 |
| Goncharova, S | 1 |
| Coyle, A | 1 |
| Vadas, P | 1 |
| Waserman, S | 1 |
| Jordana, M | 1 |
| Jones, KM | 1 |
| Niaz, MS | 1 |
| Brooks, CM | 1 |
| Roberson, SI | 1 |
| Aguinaga, MP | 1 |
| Hills, ER | 1 |
| Rice, VM | 1 |
| Bourne, P | 1 |
| Bruce, D | 1 |
| Archibong, AE | 1 |
| Larouche, G | 1 |
| Hales, BF | 1 |
| Cortes-Burgos, LA | 1 |
| Zweifel, BS | 2 |
| Settle, SL | 1 |
| Pufahl, RA | 2 |
| Anderson, GD | 2 |
| Hardy, MM | 2 |
| Weir, DE | 1 |
| Hu, G | 1 |
| Happa, FA | 1 |
| Stewart, Z | 1 |
| Muthian, S | 1 |
| Graneto, MJ | 1 |
| Masferrer, JL | 2 |
| Gallaugher, LD | 1 |
| Henry, JC | 1 |
| Kearns, PN | 1 |
| Elford, HL | 2 |
| Bergdall, VK | 1 |
| Cardounel, AJ | 1 |
| Tu, XK | 1 |
| Yang, WZ | 1 |
| Wang, CH | 1 |
| Shi, SS | 1 |
| Zhang, YL | 1 |
| Chen, CM | 1 |
| Yang, YK | 1 |
| Jin, CD | 1 |
| Wen, S | 1 |
| Lebensburger, JD | 2 |
| Pestina, TI | 2 |
| Ware, RE | 3 |
| Boyd, KL | 1 |
| Persons, DA | 2 |
| Bunn, HF | 1 |
| Nathan, DG | 2 |
| Dover, GJ | 2 |
| Hebbel, RP | 1 |
| Platt, OS | 1 |
| Rosse, WF | 1 |
| Heinemann, L | 1 |
| Simpson, GR | 1 |
| Annels, NE | 1 |
| Vile, R | 1 |
| Melcher, A | 1 |
| Prestwich, R | 1 |
| Harrington, KJ | 1 |
| Pandha, HS | 1 |
| Koeberle, A | 1 |
| Hoffmann, M | 1 |
| Dehm, F | 1 |
| Bramanti, P | 2 |
| Cuzzocrea, S | 4 |
| Kutlar, F | 1 |
| Yerigenahally, SD | 1 |
| Xue, Y | 1 |
| Moutouh-de Parseval, LA | 1 |
| Corral, LG | 1 |
| Swerdlow, PS | 1 |
| Howard, T | 1 |
| Hu, Y | 1 |
| Gao, G | 1 |
| Johnson, M | 1 |
| Zakharenko, SS | 1 |
| Tuomanen, EI | 1 |
| Rosch, JW | 1 |
| Andoh, T | 1 |
| Sakai, K | 1 |
| Urashima, M | 1 |
| Kitazawa, K | 1 |
| Honma, A | 1 |
| Kuraishi, Y | 1 |
| Scheiermann, C | 1 |
| Jang, JE | 1 |
| Prophete, C | 1 |
| McKeown, CR | 1 |
| Sharma, P | 1 |
| Sharipov, HE | 1 |
| Shen, W | 1 |
| Cline, HT | 1 |
| Kubovcakova, L | 1 |
| Lundberg, P | 1 |
| Grisouard, J | 1 |
| Hao-Shen, H | 1 |
| Romanet, V | 1 |
| Andraos, R | 1 |
| Murakami, M | 1 |
| Dirnhofer, S | 1 |
| Wagner, KU | 1 |
| Radimerski, T | 1 |
| Skoda, RC | 1 |
| Welliver, RC | 2 |
| Hintz, KH | 1 |
| Glori, M | 1 |
| Atweh, GF | 1 |
| Saunthararajah, Y | 1 |
| Fathallah, H | 1 |
| Weinberg, RS | 1 |
| Nagel, RL | 1 |
| Fabry, ME | 1 |
| Adams, RJ | 1 |
| Sumpter, LR | 1 |
| Inayat, MS | 1 |
| Yost, EE | 1 |
| Duvall, W | 1 |
| Hagan, E | 1 |
| Mayhew, CN | 1 |
| Gallicchio, VS | 1 |
| Patel, NS | 2 |
| Chatterjee, PK | 1 |
| Di Paola, R | 3 |
| Britti, D | 1 |
| Thiemermann, C | 2 |
| Collin, M | 1 |
| Hadley, J | 1 |
| Collino, M | 1 |
| Chen, X | 2 |
| Wu, N | 1 |
| Sood, S | 2 |
| Wang, P | 2 |
| Jin, Z | 1 |
| Beer, DG | 1 |
| Giordano, TJ | 1 |
| Lin, Y | 1 |
| Shih, WC | 1 |
| Lubet, RA | 1 |
| Yang, CS | 2 |
| Besson, M | 1 |
| Martin, JR | 1 |
| Li, N | 1 |
| Fang, M | 1 |
| Sun, Z | 1 |
| Myrdal, PB | 1 |
| Karlage, K | 1 |
| Kuehl, PJ | 1 |
| Angersbach, BS | 1 |
| Merrill, BA | 1 |
| Wightman, PD | 1 |
| Genovese, T | 1 |
| Mazzon, E | 1 |
| Muià, C | 1 |
| Caminiti, R | 1 |
| Hara, J | 1 |
| Fujimura, M | 1 |
| Ueda, A | 1 |
| Myou, S | 1 |
| Oribe, Y | 1 |
| Ohkura, N | 1 |
| Kita, T | 1 |
| Yasui, M | 1 |
| Kasahara, K | 1 |
| Dufield, DR | 1 |
| Liu, FC | 1 |
| Snapper, JR | 1 |
| Brigham, KL | 1 |
| Seller, MJ | 1 |
| Okunewick, JP | 1 |
| Meredith, RF | 1 |
| Brozovich, BJ | 1 |
| Seeman, PR | 1 |
| Bailie, MB | 1 |
| Dahm, LJ | 1 |
| Peters-Golden, M | 1 |
| Harris, RR | 1 |
| Carter, GW | 3 |
| Roth, RA | 1 |
| Lane, NJ | 1 |
| Thorniley, MS | 1 |
| Manek, S | 1 |
| Fuller, BJ | 1 |
| Green, CJ | 1 |
| Malo, PE | 1 |
| Bell, RL | 2 |
| Shaughnessy, TK | 1 |
| Summers, JB | 2 |
| Brooks, DW | 2 |
| Rao, TS | 1 |
| Currie, JL | 1 |
| Shaffer, AF | 1 |
| Isakson, PC | 1 |
| de Franceschi, L | 1 |
| Rouyer-Fessard, P | 1 |
| Alper, SL | 1 |
| Jouault, H | 1 |
| Brugnara, C | 1 |
| Beuzard, Y | 1 |
| Nickerson-Nutter, CL | 1 |
| Medvedeff, ED | 1 |
| Morley, TJ | 1 |
| Evans, GO | 1 |
| Goodwin, DA | 1 |
| Read, NG | 1 |
| Hodgson, ST | 1 |
| Hawksworth, GM | 1 |
| Scuri, M | 1 |
| Allegra, L | 1 |
| Abraham, WM | 1 |
| Reilly, JT | 1 |
| Paul, W | 1 |
| Smart, T | 1 |
| Barbosa, MD | 1 |
| Arthur, AS | 1 |
| Louis, RH | 1 |
| MacDonald, T | 1 |
| Polin, RS | 1 |
| Gazak, C | 1 |
| Kassell, NF | 1 |
| Volm, M | 1 |
| Kaufmann, M | 1 |
| Mattern, J | 1 |
| Wayss, K | 1 |
| McMillan, RM | 1 |
| Spruce, KE | 1 |
| Crawley, GC | 1 |
| Walker, ER | 1 |
| Foster, SJ | 1 |
| McDonagh, KT | 1 |
| Donahue, RE | 1 |
| Agricola, B | 1 |
| Byrne, E | 1 |
| Nienhuis, AW | 1 |
| Young, PR | 1 |
| Lanni, C | 1 |
| Maruyama, Y | 1 |
| Lee, TC | 1 |
| Sullivan, S | 1 |
| Soloway, MS | 1 |
| deKernion, JB | 1 |
| Rose, D | 1 |
| Persky, L | 1 |
| Skipper, HE | 1 |
| Schabel, FM | 1 |
| Mellett, LB | 1 |
| Montgomery, JA | 1 |
| Wilkoff, LJ | 1 |
| Lloyd, HH | 1 |
| Brockman, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis[NCT06065007] | 400 participants (Anticipated) | Observational | 2023-10-15 | Not yet recruiting | |||
| A Substudy of the CADRE Study: Determination of Clinical Markers in Patients With Extreme Sickle Cell Disease Phenotype[NCT03352986] | 300 participants (Anticipated) | Observational | 2017-05-15 | Recruiting | |||
| Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease[NCT02824471] | 100 participants (Anticipated) | Observational | 2014-10-31 | Recruiting | |||
| Cerebral Aneurysms: a Retrospective Study on the Experience in Our Hospital With a Comparative Analysis Between the Different Techniques Used in Its Treatment[NCT04792944] | 247 participants (Actual) | Observational | 2007-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for hydroxyurea and Disease Models, Animal
| Article | Year |
|---|---|
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Topics: Adult; Algorithms; Animals; Bone Marrow; Disease Management; Disease Models, Animal; Drugs, Investig | 2021 |
Insight into the complex pathophysiology of sickle cell anaemia and possible treatment.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; beta-Globins; Biomarkers; Blood Coagulation; Cell | 2019 |
Current advances in drug development in spinal muscular atrophy.
Topics: Animals; Child; Child, Preschool; Disease Models, Animal; Drug Design; Female; Genetic Therapy; Huma | 2013 |
Pulmonary hypertension and nitric oxide depletion in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Animals; Child; Clinical Trials as Topic; Disease Models, Animal; Echoca | 2010 |
Hemoglobinopathies.
Topics: Animals; Azacitidine; Butyrates; Cerebral Hemorrhage; Decitabine; Disease Models, Animal; DNA Methyl | 2003 |
Inflammation and airway reactivity.
Topics: Aerosols; Animals; Asthma; Disease Models, Animal; Dogs; Endotoxins; Granulocytes; Guinea Pigs; Hist | 1984 |
Pathogenesis and management of idiopathic myelofibrosis.
Topics: Anemia; Animals; Bone Marrow; Bone Marrow Transplantation; Cladribine; Combined Modality Therapy; Di | 1998 |
Other pharmaceutical agents.
Topics: Animals; Antineoplastic Agents; Antisickling Agents; Carcinogens; Cathartics; Disease Models, Animal | 2000 |
93 other studies available for hydroxyurea and Disease Models, Animal
| Article | Year |
|---|---|
Activity of hydroxyurea against Leishmania mexicana.
Topics: Animals; Antiprotozoal Agents; Cell Cycle; Disease Models, Animal; Humans; Hydroxyurea; In Vitro Tec | 2008 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
Topics: Administration, Oral; Anemia, Sickle Cell; Animals; Antisickling Agents; beta-Thalassemia; Cell Memb | 2021 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Proliferation; Disease Models, Animal; Female; | 2021 |
Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; An | 2022 |
Abnormally decreased renal Klotho is linked to endoplasmic reticulum-associated degradation in mice.
Topics: Animals; Disease Models, Animal; Endoplasmic Reticulum-Associated Degradation; Fibrosis; Humans; Hyd | 2022 |
5-Lipoxygenase Inhibition Protects Retinal Pigment Epithelium from Sodium Iodate-Induced Ferroptosis and Prevents Retinal Degeneration.
Topics: Animals; Arachidonate 5-Lipoxygenase; Cell Line; Disease Models, Animal; Ferroptosis; Gene Knockdown | 2022 |
The 5-Lipoxygenase Inhibitor Zileuton Protects Pressure Overload-Induced Cardiac Remodeling via Activating PPAR
Topics: Animals; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Hydroxyurea; Lipo | 2019 |
Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Chemical and Drug Induced Liver Injury; Collaborative Cross | 2020 |
Effects of oxidative stress on liver, brain and spinal cord of rats using L-NAME and treated with hydroxyurea. A model of sickle cell complication.
Topics: Anemia, Sickle Cell; Animals; Brain; Disease Models, Animal; Hydroxyurea; Liver; Male; NG-Nitroargin | 2020 |
Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies.
Topics: Anemia, Sickle Cell; Animals; Benzoates; Biphenyl Compounds; Cell Line, Tumor; Disease Models, Anima | 2020 |
Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Arginase; Disease Models, Animal; Hemoglobin A; H | 2021 |
5-Lipoxygenase inhibition reduces inflammation and neuronal apoptosis via AKT signaling after subarachnoid hemorrhage in rats.
Topics: Administration, Oral; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Brain Injuries; Chromones; Di | 2021 |
An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.
Topics: Aged; Animals; Blood Cell Count; Clinical Trials, Phase III as Topic; Disease Models, Animal; Diseas | 2018 |
A thalidomide-hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes.
Topics: Anemia, Sickle Cell; Animals; Cytokines; Disease Models, Animal; Fetal Hemoglobin; Hydroxyurea; Infl | 2018 |
Antidepressant-like effect of zileuton is accompanied by hippocampal neuroinflammation reduction and CREB/BDNF upregulation in lipopolysaccharide-challenged mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP; Dep | 2018 |
Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice.
Topics: Animals; Cognition; Disease Models, Animal; Hydroxyurea; Leukotriene Antagonists; Mice; Mice, Transg | 2018 |
Protective role of nimbolide against chemotherapeutic drug hydroxyurea induced genetic and oxidative damage in an animal model.
Topics: Animals; Antineoplastic Agents; Antioxidants; Chromosome Aberrations; Disease Models, Animal; Hydrox | 2018 |
Development and Characterization of a Model for Inducing Fetal Hemoglobin Production in Cynomolgus Macaques (
Topics: Anemia; Animals; Disease Models, Animal; Fetal Hemoglobin; Hydroxyurea; Macaca fascicularis; Male; P | 2018 |
Combined hydroxyurea and ET
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Disease Models, Animal; Drug Therapy, Combination | 2019 |
Vascular endothelial cell expression of JAK2
Topics: Animals; Disease Models, Animal; Endothelial Cells; Gene Expression Regulation, Enzymologic; Humans; | 2019 |
Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
Topics: Animals; Antineoplastic Agents; Arginine; Disease Models, Animal; Doxorubicin; Female; Hydroxyurea; | 2018 |
Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models.
Topics: Animals; Benzopyrans; Carboxylic Acids; Choroidal Neovascularization; Disease Models, Animal; Eye; E | 2018 |
Hydroxyurea attenuates oxidative, metabolic, and excitotoxic stress in rat hippocampal neurons and improves spatial memory in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Cells, Cultured; Disease Models | 2018 |
Acute hydroxyurea treatment reduces tubular damage following bilateral ischemia-reperfusion injury in a mouse model of sickle cell disease.
Topics: Acute Kidney Injury; Anemia, Sickle Cell; Animals; Antisickling Agents; Biomarkers; Creatinine; Dise | 2019 |
Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Arachidonate 5-Lipoxygenase | 2014 |
[Expression of 5-lipoxygenase in hippocampal CA1 neuronal damage following global cerebral ischemia in rats].
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain Ischemia; CA1 Region, Hippocampal; Disease Models, Anima | 2013 |
Targeted loss of the ATR-X syndrome protein in the limb mesenchyme of mice causes brachydactyly.
Topics: Animals; Brachydactyly; Cell Death; Chondrocytes; Disease Models, Animal; DNA Helicases; Female; For | 2013 |
Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration.
Topics: Animals; Arachidonate 5-Lipoxygenase; Cell Line; Cell Line, Tumor; Chemotaxis, Leukocyte; Disease Mo | 2015 |
Reduced plasma angiotensin II levels are reversed by hydroxyurea treatment in mice with sickle cell disease.
Topics: Anemia, Sickle Cell; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Disease Models, Anima | 2014 |
Antinociceptive properties of esculetin in non-inflammatory and inflammatory models of pain in rats.
Topics: Analgesia; Analgesics; Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Hy | 2015 |
Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
Topics: Animals; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Hydroxyurea; Inflammatory Bowel | 2015 |
Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy.
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain; Cerebellum; Cerebral Cortex; Cyclin-Dependent Kinase 5; | 2015 |
RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model.
Topics: Anemia, Sickle Cell; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhibitor | 2015 |
Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea.
Topics: Anemia, Sickle Cell; Animals; Cell Movement; Cyclic N-Oxides; Disease Models, Animal; Free Radical S | 2015 |
The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Infarction; Carotid St | 2015 |
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13.
Topics: Anemia, Sickle Cell; Animals; Asthma; Disease Models, Animal; Hydroxyurea; Interleukin-13; Leukotrie | 2016 |
Hydroxyurea Treatment and Development of the Rat Cerebellum: Effects on the Neurogenetic Profiles and Settled Patterns of Purkinje Cells and Deep Cerebellar Nuclei Neurons.
Topics: Analysis of Variance; Animals; Cerebellum; Disease Models, Animal; Dose-Response Relationship, Drug; | 2016 |
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.
Topics: Administration, Oral; Adult; Aminopyridines; Anemia, Sickle Cell; Animals; Biomarkers; Blood Platele | 2017 |
Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.
Topics: Animals; Arachidonate 5-Lipoxygenase; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immun | 2017 |
Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction.
Topics: Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Leukotriene Antagonists; | 2017 |
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
Topics: Acetophenones; Animals; Anti-Inflammatory Agents; Arachidonate 5-Lipoxygenase; Disease Models, Anima | 2017 |
Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy.
Topics: Alternative Splicing; Amino Acid Sequence; Animals; Antibodies, Monoclonal; Cells, Cultured; Disease | 2008 |
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Topics: Analysis of Variance; Animals; Benzoates; Cell Proliferation; Cells, Cultured; Cyclooxygenase Inhibi | 2008 |
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxy | 2009 |
Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions.
Topics: Allergens; Anaphylaxis; Animals; Arachis; Cholera Toxin; Cimetidine; Disease Models, Animal; Drug Th | 2009 |
Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Disease Models, Animal; Hydroxyurea; Hypogonadism | 2009 |
The impact of human superoxide dismutase 1 expression in a mouse model on the embryotoxicity of hydroxyurea.
Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Disease Models, Animal; Enzyme Inhibitors; Fem | 2009 |
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
Topics: Administration, Oral; Animals; Arachidonate 5-Lipoxygenase; Blotting, Western; Cell Line; Disease Mo | 2009 |
Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model.
Topics: Animals; Atherosclerosis; Disease Models, Animal; Enzyme Inhibitors; Hydroxamic Acids; Hydroxyurea; | 2009 |
Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats.
Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Brain; Brain Ischemia; Cerebral Infarction; Di | 2010 |
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.
Topics: Anemia, Sickle Cell; Animals; Blood Cell Count; Disease Models, Animal; Fetal Hemoglobin; Genetic Th | 2010 |
The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Disease Models, Animal; Fi | 2010 |
The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.
Topics: Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carrageenan; Cyclooxygenase 2; Dinoprostone; | 2010 |
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Disease Models, Animal; Erythropoies | 2011 |
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Child; Disease Models, Animal; E-Selectin; Female | 2012 |
Involvement of leukotriene B4 in itching in a mouse model of ocular allergy.
Topics: Allergens; Ambrosia; Animals; Conjunctivitis, Allergic; Disease Models, Animal; Glucocorticoids; His | 2012 |
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Anemia, Sickle Cell; Animals; Antisickling Agent | 2012 |
Neurogenesis is required for behavioral recovery after injury in the visual system of Xenopus laevis.
Topics: Animals; Cell Proliferation; Deoxyuridine; Disease Models, Animal; Escape Reaction; Female; Histones | 2013 |
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.
Topics: Alleles; Amino Acid Substitution; Animals; Bone Marrow Transplantation; Disease Models, Animal; Fema | 2013 |
Zileuton reduces respiratory illness and lung inflammation, during respiratory syncytial virus infection, in mice.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cell Count; Disease Models, Animal; Hydroxyurea; Inflammation | 2003 |
In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.
Topics: Animals; Antiviral Agents; Benzamidines; Bone Marrow Cells; Dideoxynucleosides; Disease Models, Anim | 2004 |
Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Topics: Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Inflammation; Intercellul | 2004 |
Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Topics: Animals; Arachidonate 5-Lipoxygenase; CD11 Antigens; CD18 Antigens; Chemotaxis, Leukocyte; Disease M | 2004 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonat | 2004 |
Centrophobism/thigmotaxis, a new role for the mushroom bodies in Drosophila.
Topics: Analysis of Variance; Animals; Animals, Genetically Modified; Behavior, Animal; Disease Models, Anim | 2005 |
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carcinogen | 2005 |
Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.
Topics: Adenoma; Administration, Inhalation; Administration, Oral; Animals; Benzo(a)pyrene; Disease Models, | 2007 |
Effects of zileuton and montelukast in mouse experimental spinal cord injury.
Topics: Acetates; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Cyclooxygenase 2; Cyclopropanes; Cysteine | 2008 |
Effect of pressure stress applied to the airway on cough-reflex sensitivity in Guinea pigs.
Topics: Animals; Biomechanical Phenomena; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Broncho | 2008 |
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Topics: Air; Animals; Arachidonate 5-Lipoxygenase; Biological Assay; Calcimycin; Carrageenan; Cell Line, Tum | 2008 |
[Effects of Epimedium sagittatum and Cistanche deserticola on DNA synthesis in "Yang-insufficiency" animal model induced by hydroxyurea].
Topics: Animals; China; Disease Models, Animal; DNA; Drug Combinations; Hydroxyurea; Male; Mice; Plant Extra | 1984 |
The cause of neural tube defects: some experiments and a hypothesis.
Topics: Animals; Disease Models, Animal; DNA; Female; Fluorouracil; Gestational Age; Hydroxyurea; Mice; Mice | 1983 |
Rauscher leukemia as a model for cancer therapy studies. II. Variation in response of splenic CFU-S between normal and Rauscher leukemic mice following exposure to hydroxyurea.
Topics: Animals; Cell Cycle; Colony-Forming Units Assay; Disease Models, Animal; Female; Hematopoietic Stem | 1980 |
Leukotrienes and alpha-naphthylisothiocyanate-induced liver injury.
Topics: 1-Naphthylisothiocyanate; Acetamides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcimycin; | 1995 |
Inhibition of leukotriene B4 synthesis does not prevent development of acute renal failure following storage and transplantation.
Topics: Acute Kidney Injury; Animals; Capillary Permeability; Creatinine; Disease Models, Animal; Eicosanoid | 1994 |
The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis.
Topics: Anaphylaxis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchoconstriction; Disease Models, | 1994 |
Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcimycin; Disease Models, Animal; Drug Evaluatio | 1993 |
Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy.
Topics: Animals; beta-Thalassemia; Body Water; Calcimycin; Calcium; Calcium Channel Blockers; Chlorides; Clo | 1996 |
The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chronic Disease; Disease | 1996 |
Structure-activity relationship for two lipoxygenase inhibitors and their potential for inducing nephrotic syndrome.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Blood Proteins; Cholesterol; Creatinine; | 1997 |
The effects of multiple dosing with zileuton on antigen-induced responses in sheep.
Topics: Airway Resistance; Animals; Asthma; Bronchial Provocation Tests; Disease Models, Animal; Drug Admini | 1998 |
Basic science and clinical trials: interview with William Paul, director of the Office of AIDS Research. Interview by John S James.
Topics: Acquired Immunodeficiency Syndrome; Animals; Clinical Trials as Topic; Disease Models, Animal; Human | 1995 |
Beyond hydroxyurea.
Topics: Animals; Antiviral Agents; Benzamidines; Dipyridamole; Disease Models, Animal; Floxuridine; Fluorour | 1995 |
The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage.
Topics: Animals; Basilar Artery; Disease Models, Animal; Enzyme Inhibitors; Hydroxyurea; Lipoxygenase Inhibi | 2001 |
[Possibilities and limits of pre-therapeutic neoplasm sensitivity cytostatics tests under short-term conditions].
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Cyclophosphamide; Dactinomycin; D | 1975 |
Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Bronchocon | 1992 |
Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate.
Topics: Administration, Oral; Anemia; Animals; Bloodletting; Butyrates; Butyric Acid; Cell Division; Chromat | 1992 |
Inhibition of leukotriene biosynthesis in the rat peritoneal cavity.
Topics: Administration, Oral; Anaphylaxis; Animals; Disease Models, Animal; Hydroxyurea; Leukotrienes; Lipox | 1991 |
Age cohort variation of tumor cells.
Topics: Animals; Cell Division; Disease Models, Animal; DNA, Neoplasm; Fluorouracil; Hydroxyurea; Lymphoma; | 1973 |
Effect of chemotherapeutic agents on bladder cancer: a new animal model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Dactinomycin; Diamin | 1973 |
Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Disease Mo | 1970 |